On the in vivo early toxic properties of Aβ25-35 peptide in the rat hippocampus: Involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression

Neurotoxicology and Teratology

Volumn 33, Issue 2, 2011, Pages 288-296

  Cuevas, Elvis ^a,c   Lantz, Susan M ^a   Tobón Velasco, J César ^c   Newport, Glenn D ^a   Wu, Qiangen ^a   Virmani, Ashraf ^b   Ali, Syed F ^a   Santamaría, Abel ^a,c  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b Sigma Tau SpA   (Italy)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Amyloid 25 35; Gene expression; Neurodegeneration; Neurotoxicity; Oxidative stress; Receptor for Advanced Glycation End Products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN[25-35]; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; NITRATE; NITRIC OXIDE; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOLIPOPROTEIN E GENE; ARTICLE; BRAIN MITOCHONDRION; CONTROLLED STUDY; COPPER CHAPERONE FOR SUPEROXIDE DISMUTASE GENE; DOWN REGULATION; FLAVIN CONTAINING MONOOXYGENASE 2 GENE; GENE; GENE EXPRESSION; HIPPOCAMPAL CA1 REGION; MALE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 2 GENE; RAT; SIGNAL TRANSDUCTION; SOLUTE CARRIER FAMILY 41 MEMBER 3 GENE; UPREGULATION;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; CA1 REGION, HIPPOCAMPAL; CELL DEATH; GENE EXPRESSION; MALE; MICROINJECTIONS; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA; NITRIC OXIDE; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

RATTUS;

EID: 79953327868     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ntt.2010.12.002     Document Type: Article

References (45)

1. Andersen J.M., Myhre O., Aarnes H., Vestad T.A., Fonnum F. Identification of the hydroxyl radical and other reactive oxygen species in human neutrophil granulocytes exposed to a fragment of the amyloid beta peptide. Free Radic Res 2003, 37(3):269-279.
2. Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004, 3:205-214.
3. Butterfield D.A., Kanski J. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid ß-peptide 1-42. Peptides 2001, 23:1299-1309.
4. Chaney M.O., Stine W.B., Kokjohn T.A., Kuo Y.M., Esh C., Rahman A., Luehrs D.C., Schmidt A.M., Stern D., Yan S.D., Roher A.E. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta 2005, 1741:199-205.
5. Deane R., Du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A.M., Armstrong D.L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003, 9(7):907-913.
6. Drouet B., Pinçon-Raymond M., Chambaz J., Pillot T. Molecular basis of Alzheimer's disease. Cell Mol Life Sci 2000, 57:705-715.
7. Granic I., Dolga A.M., Nijholt I.M., van Dijk G., Eisel U.L. Inflammation and NF-kappaB in Alzheimer's disease and diabetes. J Alzheimers Dis 2009, 16(4):809-821.
8. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 298:962-964.
9. Hayek T., Oiknine J., Brook J.G., Aviram M. Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochem Biophys Res Commun 1994, 201(3):1567-1574.
10. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M.F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D., Schmidt A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-901.
11. Iqbal K., Flory M., Khatoon S., Soininen H., Pirttila T., Lehtovirta M., Alafuzoff I., Blennow K., Andreasen N., Vanmechelen E., Grundke-Iqbal I. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005, 58:748-757.
12. Kang J., Park E.J., Jou I., Kim J.H., Joe E.H. Reactive oxygen species mediate: amyloid beta (25-35)-induced activation of BV-2 microglia. NeuroReport 2001, 12(7):1449-1452.
13. Kim T.I., Lee Y.K., Park S.G., Choi I.S., Ban J.O., Park H.K., Nam S.Y., Yun Y.W., Han S.B., Oh K.W., Hong J.T. l-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. Free Radic Biol Med 2009, 47(11):1601-1610.
14. Kuang X., Du J.R., Chen Y.S., Wang J., Wang Y.N. Protective effect of Z-ligustilide against amyloid beta-induced neurotoxicity is associated with decreased pro-inflammatory markers in rat brains. Pharmacol Biochem Behav 2009, 92(4):635-641.
15. Liu X., Luo D., Zheng M., Hao Y., Hou L., Zhang S. Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NAD(P)H oxidase and NF kappa B activation. Eur J Pharmacol 2010, 629:153-158.
16. Liu Y.Y., Liang C., Liu X., Liao B., Pan X., Ren Y., Fan M., Li M., He Z., Wu J., Wu Z. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kB pathways. Atherosclerosis 2010, 208:34-42.
17. Lue L.F., Walker D.G., Brachova L., Beach T.G., Rogers J., Schmidt A.M., Stern D.M., Yan S.D. Involvement of microglial receptor for advanced glycation end-products (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001, 171(1):29-45.
18. Lue L.F., Walker D.G., Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 2001, 22(6):945-956.
19. Maczurek A., Shanmugan K., Munch G. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease. Ann NY Acad Sci 2008, 1126:147-151.
20. Matthews R.T., Beal M.F. Increased 3-nitrotyrosine in brains of Apo E-deficient mice. Brain Res 1996, 718(1-2):181-184.
21. McGeer P.L., McGeer E.G. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 2002, 8:529-538.
22. Mendes-Sousa M., Yan S.D., Stern D., Saraiva M.J. Interaction of the Receptor for Advanced Glycation End Products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) Activation. Lab Investig 2000, 80(7):1101-1110.
23. Miller M.C., Tavares R., Johanson C.E., Hovanesian V., Donahue J.E., Gonzalez L., Silverberg G.D., Stopa E.G. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 2008, 1230:273-280.
24. Miyata M., Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996, 14(1):55-61.
25. Mruthinti S., Hill W.D., Swamy-Mruthinti S., Buccafusco J.J. Relationship between the induction of RAGE cell-surface antigen and the expression of amyloid binding sites. J Mol Neurosci 2003, 20(3):223-232.
26. Origlia N., Arancio O., Domenici L., Yan S.S. MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE. Expert Rev Neurother 2009, 9(11):1635-1645.
27. Palinski W., Ord V.A., Plump A.S., Breslow J.L., Steinberg D., Witztum J.L. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994, 14(4):605-616.
28. Parihar M.S., Hemnani T. Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 2004, 11(5):456-467.
29. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego.
30. Pike C.J., Walencewicz-Wasserman A.J., Kosmoski J., Cribbs D.H., Glabe C.G., Cotman C.W. Structure-activity analyses of beta-amyloid peptides: contributions ofthe beta 25-35 region to aggregation and neurotoxicity. J Neurochem 1995, 64:253-265.
31. Probst A., Herzig M.C., Mistl C., Ipsen S., Tolnay M. Perisomatic granules (nonplaquedystrophic dendrites) of hippocampal CA1 neurons in Alzheimer's diseaseand Pick's disease: a lesion distinct from granulovacuolar degeneration. Acta Neuropathol 2001, 102:636-644.
32. Ramasamy R., Vannucci S.J., Du-Yan S.S., Herold K., Yan S.F., Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 7:16R-28R.
33. Roehm N.W., Rodgers G.H., Hatfield S.M. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Meth 1991, 142:257-265.
34. Schmidt A.M., Stern D.M. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front Biosci 2001, 6:D1151-D1160.
35. Schmidt A.M., Sahagan B., Nelson R.B., Selmer J., Rothlein R., Bell J.M. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr Opin Investig Drugs 2009, 7:672-680.
36. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Münch G. Advanced glycation end-products and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2009, [Epub ahead of print]. doi:10.1016/j.neurobiolaging.2009.04.016.
37. Sterna D., Yana S.D., Yan S.F., Schmidt A.M. Receptor for advanced glycation end-products: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002, 54:1615-1625.
38. Storey E., Kinsella G.J., Slavin M.J. The neuropsychological diagnosis of Alzheimer's disease. J Alzheimers Dis 2001, 3:261-285.
39. Titheradge M.A. The enzymatic measurement of nitrate and nitrite. Chapter 9: Methods in Molecular Biology 1997, 83-91. Humana Press Inc, Totowa, NJ. M.A. Titheradge (Ed.).
40. Tomidokoro Y., Harigaya Y., Matsubara E., Ikeda M., Kawarabayashi T., Shirao T., Ishiguro K., Okamoto K., Younkin S.G., Shoji M. Brain Abeta amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau. J Pathol 2001, 194(4):500-506.
41. Wisniewski H.M., Wegiel J., Kotula L. Some neuropathological aspects of Alzheimer's disease and its relevance to other disciplines. Neuropathol Appl Neurobiol 1996, 22:3-11.
42. Yan S.D., Schmidt A.M., Anderson G.M., Zhang J., Brett J., Zou Y.S., Pinsky D., Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994, 269:9889-9897.
43. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt M. RAGE and Amyliod-B peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382(22):685-691.
44. Yan S.D., Bierhaus A., Nawroth P.P., Stern D.M. RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?. J Alzheimers Dis 2009, 16(4):833-843.
45. Yankner B.A. Amyloid and Alzheimer's disease cause or effect?. Neurobiol Aging 1989, 10:470-471.